Meeting
2021 ASCO Annual Meeting
PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.
Presenter
Margarita Majem, MD, PhD
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9076)
DOI
10.1200/JCO.2021.39.15_suppl.9076
Abstract #
9076
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
Speaker: Erica C. Nakajima, MD, MD
Speaker: Panel Discussion
Videos & Slides
ASCO Plenary Series
Panel Question and Answer with Drs. Ribera, Luskin, Advani, and Boissel, moderated by Dr. Schiffer
Speaker: Panel Discussion
Videos & Slides
2021 ASCO Annual Meeting
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.
Speaker: Mustafa Ozguroglu, MD